Share
Lenacapavir (Sunlenca)
All Clinical Trials
Filter by Category
- All Clinical Trials
- Clinical Studies
- Treatment-Naive
- Treatment-Experienced
- Switch/Simplification
- Dual Therapy
- Monotherapy
- PREP
- PEP
- Acute HIV
- Resistance/Virological Failure
- Pharmacology
- General Pharmacology
- Adverse Effects
- Drug Interactions
- Pregnancy/Women
- Pediatrics
- Review
Official Title A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination With Other Antiretroviral Agents in People Living With HIV
Phase Phase II
ClinicalTrials.gov NCT04143594
Treatments
Lenacapavir
Lenacapavir
Tradename:SunlencaClass:Capsid InhibitorsCategories Treatment-NaiveDual Therapy
Funding
IndustryGilead Sciences
References
- Gupta SK, Berhe M, Crofoot G, et al. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. Lancet HIV. 2023;10:e15-e23.
Official Title A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS-6207 in Combination With an Optimized Background Regimen in Heavily Treatment Experienced People Living With HIV-1 Infection With Multidrug Resistance
Phase Phase III
ClinicalTrials.gov NCT04150068
Treatments
Lenacapavir
Lenacapavir
Tradename:SunlencaClass:Capsid InhibitorsCategories Treatment-Experienced
Funding
IndustryGilead Sciences
References
- Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2022;386:1793-1803.
Lenacapavir Slide Deck
December 28, 2022
Clinical Trial Image Decks
CALIBRATE - December 28, 2022
CAPELLA - December 28, 2022